Henagliflozin on Liver Fibrosis in Patients with MASLD and T2DM

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 190 participants.

Also called NCT06762223

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 190 participants (planned count) (from the registry)
Sponsor
Xiqiao Zhou (from the registry)
Registry
  • NCT NCT06762223
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT06762223. Randomized; triple masking; primary purpose treatment. Start 2024-12-31 (anticipated); primary completion 2026-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Henagliflozin on Liver Fibrosis in Patients with MASLD and T2DM
Condition
Metabolic Dysfunction-associated Steatotic Liver Disease
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Henagliflozin 10 mg daily
Intervention (Drug)
Metformin 1700 mg daily
Intervention (Other)
Placebo of Henagliflozin
Lead sponsor
Xiqiao Zhou (class: other)
Collaborator
Jiangsu Hengrui Pharmaceutical Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct06762223
Content hash
4146b0514aec4c569d6fb81d193a173821b89fc4fb1be838c16ea75df26367a7